Commonwealth Coat of Arms of Australia

 

Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 6) 2022

I, Nigel Murray, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated  17 October 2022

Nigel Murray

Assistant Secretary

MBS Policy and Specialist Services
Medical Benefits Division

Department of Health and Aged Care

 

 

 

Contents

1 Name...............................................1

2 Commencement.........................................1

3 Authority.............................................1

4 Schedules.............................................1

Schedule 1—Amendments 2

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 2

 

 


1  Name

  This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 6) 2022.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 November 2022.

 

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1— Amendments

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1  Schedule 1 (items 73337, 73341 and 73344)

Omit “pembrolizumab”, substitute “an immunotherapy listed”

2  Schedule 2 (following item 73433)

Insert:

 

73436

A test of tumour tissue from a patient diagnosed with locally advanced or metastatic non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician to determine if the requirements relating to MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk)  status for access to tepotinib are fulfilled under the Pharmaceutical Benefits Scheme

 

397.35